Table 1 Clinical characteristics of patients with uveitis according to final diagnosis
Characteristics of patients | Median (range) or number/total (percent) in COT patients (n = 22) | Median (range) or number/total (percent) in UOT patients (n = 16) | Median (range) or number/total in OU patients (n = 23) | Median (range) or number/total in COINF patients (n = 5) | p |
|---|---|---|---|---|---|
Age | 37,5 (13–70) | 30 (19–74) | 34 (17–79) | 50,2 (16–79) | 0,523 |
Gender Female | 10/22 (45,5%) | 6/16 (37,5%) | 14/23 (60,9%) | 2/5 (40% | 0,492 |
Localization of uveitis (anterior, posterior and panuveitis) | 0/22 (0%) anterior 12/22 (54,5%) posterior 10/22 (45,5%) panuveitis | 1/16 (6,3%) anterior 14/16 (87,5%)% posterior 1/16 (6,3%) panuveitis | 5/23 (21,7%) anterior 9/23 (39,1%) posterior 9/23 (39,1%) panuveitis | 0/5 (0%) anterior 1/5 (20%) posterior 4/5 (80%) panuveitis | 0,004 |
Bilateral involvement | 3/22 (13,6%) | 2/16 (12,5%) | 7/23 (30,4%) | 2/5 (40%) | 0,351 |
Cataract | 6/22 (27,2%) | 4/16 (25%) | 8/23 (34,7%) | 1/5 (20%) | 0,655 |
Papillitis | 3/22 (13,6%) | 1/16 (6,3%) | 4/23 (17,4%) | 1/5 (20%) | 0,539 |
Total number of scars (both eyes) | 2,5 (1–11) | 2 (1–18) | 1,5 (1–4) | 2,5 (2–3) | 0,800 |
Number of inflammatory cells in vitreous humor | 2 (0–4) | 0,5 (0–4) | 1 (0–4) | 2 (0–4) | 0,403 |
Median size of scars in disk diameters | 1,53 (1–6) | 1 (1–4) | 0,9 (1–3) | 1,3 (1–2) | 0,157 |
Median number of recurrences episodes | 1,81 (0–10) | 1 (0–4) | 1,52 (0–10) | 0,6 (0–2) | 0,658 |
Number (%) of IgM serological test positive for virus (EBV, CMV, HVS1, HVS2) | 2/22 (9%) | 2/16 (18,8%) | 5/23 (21,7%) | 0/5 (0%) | 0,716 |
Number of patients with intraocular pressure > 20 mmHg | 4/22 (18,2%) | 1/16 (6,3%) | 2/23 (8,7%) | 1/5 (12,5%) | 0,236 |
Number of patients (%) with change of treatment after diagnosis | 3/22 (13,6%) | 1/16 (6,3%) | 13/23 (56.5%) | 3/5 (60%) | 0,002 |
Significant clinical improvement after treatment change | 3/3 (100%) | 1/1 (100%) | 12/13 (92,3%) | 3/3 (100%) | – |
Significant clinical improvement after 6 months of treatment (regardless of whether there was change or continuation) | 21/22 (95.4%) | 14/16 (87.5%) | 20/23 (86.95%) | 4/5 (80%) | – |
IgG for Toxoplasmosis: qualitative | 22/22 (100%) | 16/16 (100%) | 3/23 (13%) | 5/5 (100%) | – |
IgM for Toxoplasmosis: qualitative | 3/22 (13.6%) | 0/16 (0%) | 1/23 (4.34%) | 0/5 (0%) | – |
IgM for EBV: qualitative | 2/22 (9%) | 2/16 (33.3%) | 3/23 (13%) | 0/5 (0%) | – |
IgM for CMV: qualitative | 0/22 (0%) | 0/16 (0%) | 0/23 (0%) | 0/5 (0%) | – |
IgM for HSV-1: qualitative | 0/22 (0%) | 0/16 (0%) | 2/23 (8.6%) | 0/5 (0%) | – |
IgM for HSV-2: qualitative | 0/22 (0%) | 0/16 (0%) | 0/23 (0%) | 0/5 (0%) | – |